Introduction:

Lung cancer constitutes one of the main causes of death in Cuba. Most of the patients come to the health service at an advanced stage of the disease. Polychemotherapy is one of the treatments used.

Objectives:

To assess the response to treatment with cisplatin-etoposide vs. cisplatin-paclitaxel, in patients with advanced non-small cell carcinoma.

Methods:

A descriptive, prospective study was conducted in 40 patients diagnosed with advanced non-small cell carcinoma. They were randomly assigned to one of the two treatment groups: cisplatin + etoposide (n = 20) and cisplatin. + paclitaxel (n = 20) at the Pneumologic Hospital from January 2017 to September 2018.

Results:

Male patients predominated, ages ranged between 50 and 69 years, 37.5% were in stage IV. Clinical response to treatment was found in 72.5% of patients, that is, 70% in the modality of cisplatin + etoposide and 75% in cisplatin + paclitaxel. Similar percentage of objective antitumor response was observed, that is, 32.5% of the patients had partial reduction of the tumor lesion, while disease stability was observed in 32.5%. In contrast, in the remaining 35.0%, disease progression was observed.

Conclusions:

Both modalities are concluded to have similar effectiveness in the clinical-radiological evolution of persons suffering from non-microcytic carcinoma in advanced stage.

        · resumen en Español     · texto en Español     · Español ( pdf )